Christopher Gibson, serving as a director at Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), has executed a significant stock sale, moving 40,000 shares of Class A Common Stock on June 5, 2026. The transaction resulted in proceeds totaling $144,800, with each share sold at a price of $3.62. This disposition was carried out under the framework of a Rule 10b5-1 trading plan, which Gibson originally established on May 12, 2025.
The timing of this sale is notable given the current trading dynamics of RXRX shares. At the time of the transaction, the stock was trading at $3.32, representing a substantial decline from its 52-week high of $7.18. Prior to the sale, Gibson converted 40,000 shares of Class B Common Stock into Class A Common Stock. This conversion mechanism allows each share of Class B Common Stock to be converted into one share of Class A Common Stock at the holder's option, with no expiration date attached to this right. The conversion itself occurred at a price of $0 per share.
Following this series of transactions, Gibson's direct holdings now stand at 883,735 shares of Class A Common Stock. His broader portfolio includes various derivative securities and indirect holdings. Specifically, he holds Class B Common Stock through LAHWRAN-3 LLC with 386,000 shares, LAHWRAN-4 LLC with 388,000 shares, and the Gibson Family Trust with 50,000 shares. Additionally, Gibson maintains several stock options, which grant him the right to purchase Class A Common Stock at predetermined prices. These options include rights to acquire 1,050,567 shares at an exercise price of $7.25, 666,898 shares at $10.09, 813,600 shares at $8.55, 399,002 shares at $11.40, 5,436 shares at $11.40, and 282,500 shares at $2.48. These options are subject to various vesting schedules and have expiration dates ranging from 2030 to 2035.
The stock sale coincides with Recursion Pharmaceuticals' Q1 2026 earnings report. The company reported an EPS of -$0.22, which exceeded the expected loss of -$0.26. However, revenue came in at $6.47 million, significantly below the anticipated $16.28 million. This mixed financial performance highlights the ongoing challenges in scaling operations while managing cash burn.
Broader industry analysis from Jefferies also sheds light on the pharmaceutical sector. A research report emphasized the role of artificial intelligence in driving up to 50% cost reductions in drug development. This analysis was based on 42 expert call transcripts, underscoring the growing influence of AI in contract research organizations and drug development processes. The report suggests that technological advancements are becoming increasingly critical in managing development costs and improving efficiency across the sector.
InvestingPro analysis indicates that RXRX appears undervalued at current levels, noting that the company holds more cash than debt despite rapid cash burn. Investors seeking deeper insights can access detailed analysis through InvestingPro's comprehensive Pro Research Report. The stock's after-hours trading shows a slight increase to $3.31, reflecting ongoing market interest in the company's financial trajectory and strategic positioning.